Abbisko Therapeutics Co., Ltd – Trademark Portfolio

Entity Type: 16

Abbisko Therapeutics Co., Ltd holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include ABBISKO, IRPALIV, and NEUZATA.

No.3, Lane 898, HaLei Road,

China (Shanghai) Pilot Free Trade Zone 201203 Shanghai

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ABBISKO
ABBISKO
Registered 2023
IRPALIV
IRPALIV
Registered 2023
NEUZATA
NEUZATA
Registered 2023
EUPITORB
EUPITORB
Abandoned 2023
ABILIV
ABILIV
Abandoned 2023

Trademark Classifications

Abbisko Therapeutics Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Abbisko Therapeutics Co., Ltd have?

Abbisko Therapeutics Co., Ltd has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 abandoned.

What trademark classes does Abbisko Therapeutics Co., Ltd file in?

Abbisko Therapeutics Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Abbisko Therapeutics Co., Ltd's most well-known trademarks?

Abbisko Therapeutics Co., Ltd's registered trademark portfolio includes well-known marks such as ABBISKO, IRPALIV, and NEUZATA. These are among 3 currently registered trademarks in the portfolio.

What is Abbisko Therapeutics Co., Ltd's trademark registration success rate?

Abbisko Therapeutics Co., Ltd has a 60% trademark registration rate, with 3 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.